We describe the management of an 83-year-old 
C1 esterase inhibitor deficiency is a rare disorder, with implications for the anaesthetist because patients have the potential to develop lifethreatening upper airway obstruction due to angioedema. Most of the literature on this subject relates to hereditary angioedema. Such patients presenting to the anaesthetist will usually be identifiable from the history. We report a patient with no such history, who presented with macroglossia and subsequently developed airway obstruction. Investigation led to a diagnosis of acquired C1 esterase inhibitor deficiency associated with an underlying malignancy.
CASE REPORT
An 83-year-old woman presented to the Accident and Emergency Department with a swollen tongue. There was no previous or family history of angioedema. She was alert and orientated, was able to speak and was not in respiratory distress. Adrenaline 500 µg and intramuscularly intravenous hydrocortisone 200 mg, chlorpheniramine 10 mg and ranitidine 50 mg were administered. The patient had been admitted to hospital 18 months previously with left ventricular failure and at that time an abnormal differential leucocyte count had been noted (1% myelocytes and 1.5% metamyelocytes). The patient also had a history of chronic obstructive pulmonary disease and hypothyroidism. Her medication comprised thyroxine, frusemide and inhaled salbutamol.
Despite treatment, the patient developed respiratory distress and anaesthetic assistance was sought. Initial assessment demonstrated gross macroglossia, with the tongue protruding from the oral cavity. The patient was tachypnoeic with inspiratory stridor and she was transferred to the operating theatre for airway management. Awake fibreoptic intubation was planned. Preparations were made for trans-tracheal jet ventilation and/or emergency cricothyroidotomy should fibreoptic intubation fail. Topical anaesthesia of the airway was achieved and oxygen was administered via the right nostril. A 6.0 mm cuffed endotracheal tube was passed over the fibreoptic intubating laryngoscope and the latter was then inserted into the left nostril. Despite gross macroglossia, the patient's larynx and trachea were not oedematous and tracheal intubation was successful. The patient was then sedated and transferred to the Intensive Care Unit (ICU).
Immunological investigation showed hypogammaglobulinaemia, a complement C1q level of 0.04 g/l (normal range 0.08-0.16 g/l), C1 esterase inhibitor <0.04 g/l (normal range 0.28-0.50 g/l) and complement C4 <0.01 g/l (normal range 0.13-0.43 g/l). Complement C3, serum IgM, IgE and mast cell tryptase remained within the normal range (Table 1) . Urinary methylhistamine was elevated at 24 hours post-presentation but further investigation showed that this was likely to be due to an analytical error secondary to administration of a large volume of fluid during resuscitation. C1 esterase inhibitor concentrate 1500 plasma units (TIM-3, Baxter-AG, Vienna, Austria) was administered with resolution of the macroglossia. Haematological investigation showed a large monoclonal population of lymphocytes in keeping with a low-grade non-Hodgkin's lymphoma. Full characterization of the lymphoma was neither possible nor appropriate whilst the patient continued to be ventilator-dependent.
Duration of ventilation was protracted due, in part, to a Pseudomonas aeruginosa ventilator-associated pneumonia and the patient failed to wean from ventilatory support. With the agreement of the patient's family and with close attention to comfort measures, intensive therapy was withdrawn after 31 days and the patient died.
DISCUSSION
Complement C1 is the first component of the classical pathway of complement activation and has three subunits: C1q, C1r and C1s. The pathway is activated when C1q binds to immune complexes of IgM or IgG bound to antigen 1 . Triggering of the cascade leads to the formation of C1 esterase (Figure 1 ). C1 esterase inhibitor (C1-INH) is the major regulatory protein of the initial activation process of complement and is a hepatocyte-synthesized (2-globulin acting to inhibit complement C1, specifically C1r and C1s.
Angioedema is an acute, localized, non-pitting, non-pruritic, non-erythematous, demarcated swelling of subcutaneous or submucosal tissue 2 . The upper airway, extremities and intestinal tract are usually affected. Trauma is a frequent precipitating factor that allows exposed collagen to activate Hageman factor. This results in kinin generation, fibrinolysis and coagulation. The absence of C1-INH allows C1 esterase and plasmin to generate activated C2 kinin. It is either C2 kinin or bradykinin that is thought to cause the increase in vascular permeability that leads to angioedema 3 . The investigation of a patient with a history of angioedema is summarized in Figure 2 . Although hereditary angioedema had been described previously 4 , it was not until 1972 that Caldwell et al reported an acquired form of the disease 5 . Most cases of acquired C1 esterase inhibitor deficiency are associated with B-cell lymphoproliferative disorders (acquired angioedema type 1). These patients have antibodies to the monoclonal immunoglobulin expressed on the surface of malignant B-cells. This leads to activation of complement C1 (specifically C1q) and consumption of C1-INH resulting in a quantitative deficiency 3, 6, 7 . Acquired angioedema type 2 is a result of specific auto-antibodies directed at the active site of the C1-INH molecule 8 . This leads to consumption of C1q and decreased activity of C1-INH despite normal C1 esterase inhibitor antigen 3 . Therefore, the presence of a normal C1-INH level in conjunction with decreased C1q, C2 and C4 levels is indicative of a diagnosis of acquired angioedema type 2.
The low C1 concentration, late onset and absent family history serve to distinguish between the acquired and hereditary condition 9 . Following diagnosis, the patient should be investigated for an underlying malignancy 3 and if no malignancy is found, should undergo regular review, because there can be a long interval between the onset of angioedema and the appearance of neoplasm.
Management of acquired angioedema depends on whether treatment is required for an acute attack or for prophylaxis. If oedema is mild, oxygen and observation in a high dependency unit are required until symptoms resolve. Urgent airway management necessitates full resuscitation equipment and preparation for emergency tracheostomy. The laryngeal mask airway has no demonstrated role in this setting. Fibreoptic tracheal intubation may not be possible in the presence of severe airway obstruction and declining oxygen saturation. Swelling may extend into the airway so that even tracheostomy may be ineffective. Death is inevitiable without specific C1 esterase inhibitor replacement 12 . A typical dose of purified C1 esterase inhibitor concentrate is 1000 to 1500 plasma units intravenously. However, patients with acquired angioedema may show a diminished response to this treatment.
For emergency surgery, C1 esterase inhibitor concentrate is also the best prophylaxis. Glucocorticoids, antihistamines and/or adrenaline are ineffective both for acute management 9 and before emergency procedures. The use of fresh-frozen plasma (FFP) for both the treatment and prophylaxis of angioedema has been advocated because it contains C1-INH 10 . However, because FFP also contains complements C2 and C4, an acute attack may be exacerbated and the potential for virus transmission exists 11 . Prior to elective surgery, the attenuated androgens danazol and stanozolol act to increase the hepatic production of C1 esterase inhibitor. Danazol appears to be safe and effective but levels of C2, C4 and C1q may remain low despite treatment 13 . It has been used for long-term prophylaxis of hereditary angioedema, but treatment had been associated with hepatocellular carcinoma 14 . Patients with acquired angioedema may either not respond or become refractory to treatment with androgens and a higher dose than the typical adult dose of 600 mg/day may be required. This may be secondary to inactivation of C1-INH by auto-antibodies 11 . The antifibrinolytic agents tranexamic acid and ε-aminocaproic acid act to inhibit plasminogen activation and plasmin activity and limit the activation of C1. Cugno et al 15 demonstrated that therapy with antifibrinolytic agents reduced the frequency and intensity of symptoms in patients with acquired angioedema type 2. It was thought that the continuous activation of the contact and fibrinolytic systems was counteracted by antifibrinolytics. Sideeffects include muscle aches, fatigue and postural hypertension. Furthermore, the danger of thromboembolism precludes their routine use for perioperative prophylaxis in patients with haematological malignancies. Finally, treatment with interferongamma has been shown to increase hepatic synthesis of C1-INH 11 . In conclusion, this case highlights the potential for angioedema due to acquired C1 esterase inhibitor deficiency to cause acute upper airway obstruction. At first presentation, the clinical features may resemble an allergic reaction. Management involves not only skilled airway maintenance and the administration of C1 esterase inhibitor concentrate but the patient should also be investigated for an underlying lymphoproliferative disorder. Diagnosis of C1 esterase inhibitor deficiency also allows consideration of future prophylaxis with C1 esterase inhibitor concentrate and/or attenuated androgens.
